MCA stability tool

Check whether tablets and capsules are suitable for a multi-compartment compliance aid (MCA), and build a list to print.

Browse medicines A to Z

A (medicines beginning with A) B (medicines beginning with B) C (medicines beginning with C) D (medicines beginning with D) E (medicines beginning with E) F (medicines beginning with F) G (medicines beginning with G) H (medicines beginning with H) I (medicines beginning with I) K (medicines beginning with K) L (medicines beginning with L) M (medicines beginning with M) N (medicines beginning with N) O (medicines beginning with O) P (medicines beginning with P) Q (medicines beginning with Q) R (medicines beginning with R) S (medicines beginning with S) T (medicines beginning with T) U (medicines beginning with U) V (medicines beginning with V) W (medicines beginning with W) X (medicines beginning with X) Y (medicines beginning with Y) Z (medicines beginning with Z)

Medicines beginning with A

Aliskiren

Aliskiren 150mg tablets

Use with caution

Stability notes for Aliskiren 150mg tablets

Protect from moisture.

Provenance

This compatibility recommendation is derived from Rasilez 150mg tablets (Noden Pharma DAC).

Suppliers

Rasilez 150mg tablets (CST Pharma Ltd)
Rasilez 150mg tablets (Sigma Pharmaceuticals Plc)

Aliskiren 300mg tablets

Use with caution

Stability notes for Aliskiren 300mg tablets

Protect from moisture.

Provenance

This compatibility recommendation is derived from Rasilez 300mg tablets (Noden Pharma DAC).

Suppliers

Rasilez 300mg tablets (CST Pharma Ltd)
Rasilez 300mg tablets (Sigma Pharmaceuticals Plc)

What the ratings mean

Compatible
Suitable for use. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label.
Use with caution
Suitable with mitigations. Keep in MCA for shortest possible time: no more than 5 weeks for non-airtight; 8 weeks for airtight. Use likely to be off-label and supported by limited data.
Incompatible
Medicines under this category are not suitable for use in MCAs.
No stability information
These medicines have not been reviewed by SPS.